Data consistently shows that individuals with mental health disorders are more likely to smoke than those without, making it crucial to include them in clinical trials related to smoking cessation. Unfortunately, the reality seems to be the opposite. The article, titled "Inequities in smoking cessation clinical trials testing pharmacotherapy: excluding smokers with mental health disorders," aims to investigate the practice and reasons for excluding smokers with mental health disorders from such clinical trials.
A research team analyzed the Cochrane systematic review database as of September 2020 to obtain an evaluation of drug therapy for smoking cessation. "We included 279 RCTs from 13 Cochrane reviews. In all studies, 51 (18.3%) explicitly excluded participants with any MHD, 152 (54.5%) conditionally excluded based on certain MHD criteria, and 76 (27.2%) provided insufficient information to determine inclusion or exclusion. The study found that the likelihood of conditionally excluding smokers with MHDs was 3.33 times higher (95% CI 1.38 to 8.01, p=0.007) in studies on anti-depressant drugs for smoking cessation compared to studies on nicotine replacement therapy," the researchers reported.
In fact, their conclusion was that clinical trials examining the safety and effectiveness of smoking cessation medications lacked sufficient representation from smokers with MHD, but there was not enough data collected to explain why. The study emphasized the importance of promoting participation of this minority group in trials.
Meanwhile, other studies have found that individuals with mental health issues are more likely to smoke and have a harder time quitting compared to those without such conditions. As a result, they benefit greatly from additional support in quitting and accessing safer alternatives, at minimum decreasing their risk of smoking-related illnesses.
However, an article in the Psychiatric Times discusses important factors mental health professionals should bear in mind when using e-cigarettes, noting the presence of dangerous elements such as zinc, lead, chromium, manganese, and copper in various e-cigarette products. The article, written by Dr. Catherine Striley, Associate Professor and Director of Psychiatric Epidemiology at the University of Florida, explains that while the majority of ingredients in e-liquids may be safe to ingest, they could potentially harm the lungs and cardiovascular system.
Statement
This article is compiled from third-party information and is intended solely for industry exchange and learning.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of its contents. The translation of this article is intended only for industry research and communication purposes.
Due to limitations in translation ability, the translated article may not fully reflect the original. Please refer to the original article for accuracy.
In regards to any domestic, Hong Kong, Macau, Taiwan, or international issues, 2FIRSTS maintains full alignment with the Chinese government.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
